{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:05:56Z","timestamp":1790067956935,"version":"4.0.1"},"reference-count":35,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Metastatic colorectal cancer (mCRC) is biologically heterogeneous, resulting in variable outcomes despite similar disease burden and treatment. Although metastasectomy offers the only potentially curative option for selected patients, surgical selection remains largely anatomy based. Whether biological factors continue to influence outcomes after resection remains unclear. Methods: We retrospectively analysed 290 consecutive patients with stage IV colorectal adenocarcinoma treated at a Brazilian tertiary oncology centre (2003\u20132019). Tumour sidedness, RAS mutational status, and metastasectomy were evaluated for overall survival (OS) using Kaplan\u2013Meier analysis and multivariable Cox regression in the overall cohort and the metastasectomy subgroup. Results: Median OS was 40.2 months. Patients undergoing metastasectomy had significantly longer survival than those managed non-operatively (median 116.0 vs. 30.1 months; 5-year OS 63% vs. 14%; p &lt; 0.001). The following variables remained independently associated with improved survival: metastasectomy (HR 4.58, 95% CI 2.82\u20137.44; p &lt; 0.001), RAS status (wild type vs. mutated: HR 2.77, 95% CI 1.65\u20134.64; p &lt; 0.001), age (&gt;70 ys vs. \u2264 70 HR 0.58, 95% CI 0.37\u20130.92; p = 0.021) and metastatic presentation (synchronous vs. metachronous: HR 0.61 95% CI 0.39\u20130.95; p = 0.028). RAS status remained associated with survival in patients undergoing metastasectomy (HR 3.75, 95% CI 1.46\u20139.60; p = 0.006). Conclusions: Tumour biology remains a dominant determinant of survival in mCRC even after metastasectomy. These data challenge purely anatomy-based surgical paradigms and support integrating molecular and clinicopathological risk into post-resection management and treatment planning.<\/jats:p>","DOI":"10.3390\/cancers18193070","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:17:54Z","timestamp":1790065074000},"page":"3070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Tumour Biology into Surgical Decision-Making for Metastatic Colorectal Cancer: A Real-World Cohort Analysis Adapted for Clinical Colorectal Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Mariana Paula Cunha","family":"Gon\u00e7alves","sequence":"first","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"},{"name":"Thoracic and Gastrointestinal Oncology, Grupo Orizonti, Belo Horizonte 30210-080, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique Faria Silva","family":"Trocoli-Couto","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Henrique","family":"Marchiodi","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Toledo Bernardo","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuiti Pedro Henrique","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-290X","authenticated-orcid":false,"given":"Henrique Ara\u00fajo","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-0427","authenticated-orcid":false,"given":"Vivian","family":"Resende","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: A review and evidence-based algorithm","volume":"22","author":"Studiale","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00428-024-03746-3","article-title":"Molecular pathological classification of colorectal cancer: An update","volume":"484","author":"Dunne","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF\u2014A tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2018.03.003","article-title":"The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis","volume":"125","author":"Ciliberto","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Belias, M., Sasaki, K., Wang, J., Andreatos, N., Kamphues, C., Kyriakos, G., Seeliger, H., Beyer, K., Kreis, M.E., and Margonis, G.A. (2022). Is Laterality Prognostic in Resected KRAS-Mutated Colorectal Liver Metastases? A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14030799"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.jgo.2023.101624","article-title":"Prognostic relevance of sidedness in older patients with colon cancer: A review and pooled analysis of 227,218 patients","volume":"15","author":"Petrelli","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Waldstein, S., Spengler, M., Pinchuk, I.V., and Yee, N.S. (2023). Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment. J. Pers. Med., 13.","DOI":"10.3390\/jpm13071114"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2026.2960","article-title":"Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis","volume":"25","author":"Wu","year":"2026","journal-title":"Mol. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2024.08.011","article-title":"Surgical Management of Colorectal Cancer Liver Metastases","volume":"39","author":"Padmanabhan","year":"2025","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pourfaraji, S.M., Moghadam, M.N., Moradi, A.M., Shirmard, F.O., Mohammadzadeh, N., and Jafarian, A. (2024). Long-term survival after hepatic resection for colorectal liver metastases: A single-center study in Iran. BMC Surg., 24.","DOI":"10.1186\/s12893-024-02420-4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO-25-01231","article-title":"Randomized Phase II\/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603","volume":"44","author":"Kanemitsu","year":"2026","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3748\/wjg.v30.i7.663","article-title":"Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis","volume":"30","author":"Cheng","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10217","DOI":"10.1038\/s41467-024-54460-2","article-title":"Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: A randomized phase II DEEPER trial","volume":"15","author":"Shiozawa","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115388","DOI":"10.1016\/j.ejca.2025.115388","article-title":"FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3\/AIO KRK0306","volume":"220","author":"Holch","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jamaoncol.2024.5174","article-title":"First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases","volume":"11","author":"Bond","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_22","first-page":"e240029","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12957-025-03755-9","article-title":"Mutational status of RAS, SMAD4 and APC predicts survival after resection of colorectal liver metastases in Chinese patients: Prognostic stratification based on genetic sequencing data of multiple somatic genes","volume":"23","author":"Chen","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/bjs\/znab086","article-title":"Contour prognostic model for predicting survival after resection of colorectal liver metastases: Development and multicentre validation study using largest diameter and number of metastases with RAS mutation status","volume":"108","author":"Kawaguchi","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.critrevonc.2026.105180","article-title":"Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis","volume":"220","author":"Kuznetsova","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Lonardi","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Engstrand, J., Nilsson, H., Str\u00f6mberg, C., Jonas, E., and Freedman, J. (2018). Colorectal cancer liver metastases\u2014A population-based study on incidence, management and survival. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3925-x"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1575","DOI":"10.1590\/0102-672020210001e1578","article-title":"Primary tumor lymphovascular invasion negatively affects survival after colorectal liver metastasis resection","volume":"34","author":"Campanati","year":"2021","journal-title":"Arq. Bras. Cir. Dig."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:34:30Z","timestamp":1790066070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":35,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193070"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193070","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}